Celestial Biolabs Peer Comparison
NSE: CELESTIAL | BSE: 532871
₹1.75
₹-0.05
(-2.78%)
As on 11-Mar-2020IST
Market cap
₹5 Cr
Revenue (TTM)
₹0 Cr
P/E Ratio
--
P/B Ratio
0
Div. Yield
0 %
Edit
| Celestial Biolabs | Wockhardt | Rubicon Research | Acutaas Chemicals | Piramal Pharma | |
|---|---|---|---|---|---|
Market cap (₹ Cr) |
5 | 35,548 | 28,659 | 28,019 | 28,577 |
Revenue (₹ Cr) |
0 | 3,564 | 1,936 | 1,462 | 9,205 |
Net Profit (₹ Cr) |
-0.41 | 414.00 | 288.22 | 387.35 | -371.81 |
Net Margin (%) |
-308.96 | 11.23 | 14.79 | 26.01 | -3.93 |
RoE (%) |
-15.00 | 8.38 | 29.77 | 25.18 | -3.85 |
Price to Earnings |
-- | 86.91 | 99.43 | 72.55 | -- |
Price-To-Book |
0.05 | 7.06 | 21.35 | 16.24 | 3.57 |
Income Statement (₹ Cr)
| Celestial Biolabs | Wockhardt | Rubicon Research | Acutaas Chemicals | Piramal Pharma | |
|---|---|---|---|---|---|
|
Operating Revenue
|
0.17 | 2,651.00 | 393.52 | 616.73 | 7,081.55 |
|
Total Income
|
0.17 | 2,773.00 | 419.00 | 621.05 | 7,306.66 |
|
Total Expenditure
|
0.71 | 2,550.00 | 375.03 | 494.13 | 6,453.31 |
|
EBITDA
|
-0.54 | 101.00 | 18.49 | 122.61 | 628.24 |
|
Depreciation
|
0.03 | 251.00 | 36.06 | 12.34 | 676.69 |
|
EBIT
|
-0.57 | -150.00 | -17.57 | 110.26 | -48.45 |
|
Interest
|
0.01 | 302.00 | 18.96 | 2.41 | 344.18 |
|
Other Income
|
-- | 122.00 | 25.48 | 4.32 | 225.11 |
|
Exceptional Items
|
-- | -294.00 | -- | -- | -6.96 |
|
Profit before Tax
|
-0.58 | -624.00 | -11.05 | 112.17 | -120.15 |
|
Provision for Tax
|
-- | -3.00 | 5.84 | 28.88 | 66.31 |
|
Profit after Tax
|
-0.58 | -621.00 | -16.89 | 83.29 | -186.46 |
Liabilities (₹ Cr)
| Celestial Biolabs | Wockhardt | Rubicon Research | Acutaas Chemicals | Piramal Pharma | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
2.77 | 3,354.00 | 286.38 | 593.96 | 6,773.50 |
|
Minority Interest
|
0.00 | 308.00 | -- | -- | -- |
|
Non-Current Liabilities
|
8.98 | -22.00 | 102.01 | 10.13 | 3,812.00 |
|
Current Liabilities
|
5.49 | 3,435.00 | 361.32 | 162.85 | 3,851.04 |
|
Total Liabilities
|
17.24 | 7,651.00 | 749.70 | 766.94 | 14,566.53 |
Assets (₹ Cr)
| Celestial Biolabs | Wockhardt | Rubicon Research | Acutaas Chemicals | Piramal Pharma | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
12.90 | 4,867.00 | 248.12 | 309.81 | 9,593.07 |
|
Current Assets
|
4.34 | 1,914.00 | 501.59 | 457.13 | 4,843.47 |
|
Total Assets
|
17.24 | 7,651.00 | 749.70 | 766.94 | 14,566.53 |
|
Total Debt*
|
12.03 | 1,887.00 | 317.91 | 3.60 | 5,504.77 |
|
Net Current Assets
|
-1.15 | -1,521.00 | 140.27 | 294.28 | 992.43 |
|
Contingent Liabilities
|
1.29 | 866.26 | 9.05 | 2.70 | 57.32 |
Cashflow (₹ Cr)
| Celestial Biolabs | Wockhardt | Rubicon Research | Acutaas Chemicals | Piramal Pharma | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
-0.36 | 153.00 | -74.75 | 65.53 | 483.89 |
|
Cash Flow from Investing Activities
|
-0.01 | -125.00 | -33.82 | -33.04 | -1,338.78 |
|
Cash from Financing Activities
|
0.38 | -315.00 | 122.81 | -12.25 | 817.79 |
|
Net Cash Inflow / Outflow
|
0.01 | -287.00 | 14.24 | 20.24 | -37.10 |
Ratios
Profitability Ratios
| Celestial Biolabs | Wockhardt | Rubicon Research | Acutaas Chemicals | Piramal Pharma | |
|---|---|---|---|---|---|
|
ROCE (%)
|
-3.86 | -5.88 | 1.47 | 20.45 | 1.95 |
|
ROE (%)
|
-18.99 | -17.32 | -5.98 | 14.92 | -2.77 |
|
ROA (%)
|
-3.38 | -8.42 | -2.58 | 11.68 | -1.37 |
|
EBIT Margin (%)
|
-322.94 | 8.41 | 11.17 | 20.58 | 12.05 |
|
Net Margin (%)
|
-344.64 | -22.39 | -4.03 | 13.41 | -2.55 |
|
Cash Profit Margin (%)
|
-327.86 | -8.66 | 4.87 | 15.51 | 6.05 |
Growth Ratios
| Celestial Biolabs | Wockhardt | Rubicon Research | Acutaas Chemicals | Piramal Pharma | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
14.37 | -17.93 | 25.50 | 18.57 | 7.97 |
|
EBIT Growth (%)
|
-61.14 | -29.87 | 296.46 | 17.59 | -30.36 |
|
Net Profit Growth (%)
|
-41.98 | -122.58 | 74.84 | 15.77 | -149.60 |
|
EPS Growth (%)
|
-40.82 | -129.10 | 74.84 | 15.77 | -149.29 |
|
Book Value Growth (%)
|
-17.21 | -12.87 | -7.28 | 13.73 | 1.15 |
Valuation Ratios
| Celestial Biolabs | Wockhardt | Rubicon Research | Acutaas Chemicals | Piramal Pharma | |
|---|---|---|---|---|---|
|
Price / Earnings
|
0.00 | 0.00 | 0.00 | 19.44 | 0.00 |
|
Price / Book Value
|
0.00 | 0.66 | 0.00 | 5.45 | 1.21 |
|
Dividend Yield (%)
|
-- | 0.00 | -- | 0.34 | 0.00 |
|
EV/EBITDA
|
-63.50 | 17.85 | 6.01 | 25.09 | 15.66 |
|
Market Cap (₹ Cr)
|
0.00 | 2,216.77 | 0.00 | 3,239.09 | 8,165.74 |
Solvency Ratios
| Celestial Biolabs | Wockhardt | Rubicon Research | Acutaas Chemicals | Piramal Pharma | |
|---|---|---|---|---|---|
|
Debt to Equity
|
4.34 | 0.57 | 1.17 | 0.01 | 0.81 |
|
Short term debt to equity ratio
|
1.10 | 0.40 | 0.68 | 0.00 | 0.19 |
|
Current Ratio
|
0.79 | 0.56 | 1.39 | 2.81 | 1.26 |
|
Quick Ratio
|
0.78 | 0.37 | 0.93 | 2.08 | 0.82 |
|
Interest Coverage
|
-69.05 | -1.07 | 0.42 | 47.50 | 0.65 |
Operating Efficiency Ratios
| Celestial Biolabs | Wockhardt | Rubicon Research | Acutaas Chemicals | Piramal Pharma | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
2,197.75 | 30.06 | 57.17 | 37.34 | 25.41 |
|
Asset Turnover
|
0.01 | 0.58 | 0.60 | 0.87 | 0.60 |
|
Receivable days
|
8,157.22 | 73.25 | 169.07 | 116.58 | 80.70 |
|
Inventory Days
|
89.36 | 60.95 | 119.09 | 68.46 | 69.11 |
|
Payable days
|
1,398.94 | 293.71 | 280.34 | 143.66 | 149.81 |
|
Cash Conversion Cycle
|
6,847.64 | -159.51 | 7.82 | 41.38 | 0.00 |
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
loading...
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
